High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase two study

G. Rosti, L. Albertazzi, R. Salvioni, G. Pizzocaro, G. L. Cetto, M. A. Bassetto, M. Marangolo

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In this paper, the first Italian multicentre experience with high-dose chemotherapy and ABMT in germ cell cancer is presented. Twenty-eight patients underwent treatment with a carboplatin-etoposide w/o ifosfamide high-dose combination. Seventeen patients were in progression of disease, 9 were responsive to salvage treatments or failed to achieve CR to front line, and 2 had stable disease (both with an elevated marker level) at the time of transplantation. Five patients, all of whom were in sensitive relapse at transplantation, are alive and disease-free at > 17 months' follow-up. Two patients died 15 days after ABMT, one of veno-occlusive disease and one of rapid uncontrolled tumor progression. In highly pretreated patients this schedule seems to provide an option of cure for a cohort of patients failing to achieve CR to standard salvage regimens for germ cell cancer. Definitive conclusions may eventually be drawn with a more homogeneous group of patients. This type of approach should continue to be taken in sensitive relapse patients only, as responses in progressive cases are very transient, with virtually no cures. The question of whether high-dose programs are better than standard chemotherapy will in any case be answered only in a randomized prospective trial.

Original languageEnglish
Pages (from-to)809-812
Number of pages4
JournalAnnals of Oncology
Volume3
Issue number10
Publication statusPublished - 1992

Fingerprint

Autologous Transplantation
Germ Cell and Embryonal Neoplasms
Bone Marrow Transplantation
Drug Therapy
Transplantation
Recurrence
Salvage Therapy
Ifosfamide
Carboplatin
Etoposide
Disease Progression
Appointments and Schedules
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rosti, G., Albertazzi, L., Salvioni, R., Pizzocaro, G., Cetto, G. L., Bassetto, M. A., & Marangolo, M. (1992). High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase two study. Annals of Oncology, 3(10), 809-812.

High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors : A phase two study. / Rosti, G.; Albertazzi, L.; Salvioni, R.; Pizzocaro, G.; Cetto, G. L.; Bassetto, M. A.; Marangolo, M.

In: Annals of Oncology, Vol. 3, No. 10, 1992, p. 809-812.

Research output: Contribution to journalArticle

Rosti, G, Albertazzi, L, Salvioni, R, Pizzocaro, G, Cetto, GL, Bassetto, MA & Marangolo, M 1992, 'High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase two study', Annals of Oncology, vol. 3, no. 10, pp. 809-812.
Rosti, G. ; Albertazzi, L. ; Salvioni, R. ; Pizzocaro, G. ; Cetto, G. L. ; Bassetto, M. A. ; Marangolo, M. / High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors : A phase two study. In: Annals of Oncology. 1992 ; Vol. 3, No. 10. pp. 809-812.
@article{ae18ce22104c4b9cb03d4d2f536f2a44,
title = "High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase two study",
abstract = "In this paper, the first Italian multicentre experience with high-dose chemotherapy and ABMT in germ cell cancer is presented. Twenty-eight patients underwent treatment with a carboplatin-etoposide w/o ifosfamide high-dose combination. Seventeen patients were in progression of disease, 9 were responsive to salvage treatments or failed to achieve CR to front line, and 2 had stable disease (both with an elevated marker level) at the time of transplantation. Five patients, all of whom were in sensitive relapse at transplantation, are alive and disease-free at > 17 months' follow-up. Two patients died 15 days after ABMT, one of veno-occlusive disease and one of rapid uncontrolled tumor progression. In highly pretreated patients this schedule seems to provide an option of cure for a cohort of patients failing to achieve CR to standard salvage regimens for germ cell cancer. Definitive conclusions may eventually be drawn with a more homogeneous group of patients. This type of approach should continue to be taken in sensitive relapse patients only, as responses in progressive cases are very transient, with virtually no cures. The question of whether high-dose programs are better than standard chemotherapy will in any case be answered only in a randomized prospective trial.",
author = "G. Rosti and L. Albertazzi and R. Salvioni and G. Pizzocaro and Cetto, {G. L.} and Bassetto, {M. A.} and M. Marangolo",
year = "1992",
language = "English",
volume = "3",
pages = "809--812",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors

T2 - A phase two study

AU - Rosti, G.

AU - Albertazzi, L.

AU - Salvioni, R.

AU - Pizzocaro, G.

AU - Cetto, G. L.

AU - Bassetto, M. A.

AU - Marangolo, M.

PY - 1992

Y1 - 1992

N2 - In this paper, the first Italian multicentre experience with high-dose chemotherapy and ABMT in germ cell cancer is presented. Twenty-eight patients underwent treatment with a carboplatin-etoposide w/o ifosfamide high-dose combination. Seventeen patients were in progression of disease, 9 were responsive to salvage treatments or failed to achieve CR to front line, and 2 had stable disease (both with an elevated marker level) at the time of transplantation. Five patients, all of whom were in sensitive relapse at transplantation, are alive and disease-free at > 17 months' follow-up. Two patients died 15 days after ABMT, one of veno-occlusive disease and one of rapid uncontrolled tumor progression. In highly pretreated patients this schedule seems to provide an option of cure for a cohort of patients failing to achieve CR to standard salvage regimens for germ cell cancer. Definitive conclusions may eventually be drawn with a more homogeneous group of patients. This type of approach should continue to be taken in sensitive relapse patients only, as responses in progressive cases are very transient, with virtually no cures. The question of whether high-dose programs are better than standard chemotherapy will in any case be answered only in a randomized prospective trial.

AB - In this paper, the first Italian multicentre experience with high-dose chemotherapy and ABMT in germ cell cancer is presented. Twenty-eight patients underwent treatment with a carboplatin-etoposide w/o ifosfamide high-dose combination. Seventeen patients were in progression of disease, 9 were responsive to salvage treatments or failed to achieve CR to front line, and 2 had stable disease (both with an elevated marker level) at the time of transplantation. Five patients, all of whom were in sensitive relapse at transplantation, are alive and disease-free at > 17 months' follow-up. Two patients died 15 days after ABMT, one of veno-occlusive disease and one of rapid uncontrolled tumor progression. In highly pretreated patients this schedule seems to provide an option of cure for a cohort of patients failing to achieve CR to standard salvage regimens for germ cell cancer. Definitive conclusions may eventually be drawn with a more homogeneous group of patients. This type of approach should continue to be taken in sensitive relapse patients only, as responses in progressive cases are very transient, with virtually no cures. The question of whether high-dose programs are better than standard chemotherapy will in any case be answered only in a randomized prospective trial.

UR - http://www.scopus.com/inward/record.url?scp=0026676264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026676264&partnerID=8YFLogxK

M3 - Article

C2 - 1337464

AN - SCOPUS:0026676264

VL - 3

SP - 809

EP - 812

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -